Biofrontera Stock (NASDAQ:BFRI)
Previous Close
$1.08
52W Range
$0.54 - $1.19
50D Avg
$0.89
200D Avg
$0.90
Market Cap
$12.81M
Avg Vol (3M)
$374.82K
Beta
0.64
Div Yield
-
BFRI Company Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Government and Payor Rebates | $310.00K | $264.00K | $157.00K |
| Co-pay Assistance Program | $165.00K | $675.00K | - |
| Returns | $52.00K | $53.00K | $180.00K |
| Prompt Pay Discounts | $6.00K | $67.00K | $7.00K |
| CoPay Assistance Program | - | - | $374.00K |
Fiscal year ends in Dec 25 | Currency in USD